SCHEMBL19834411

SCHEMBL19834411

OCc1cnc(-c2ccc(Cl)nc2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
NOTUM Q6P988 3/20 0.46
PIK3CD O00329 1/20 0.41
CYP2A6 P11509 1/20 0.39
HDAC1 Q13547 6/20 0.37
HDAC2 Q92769 6/20 0.37
HDAC3 O15379 5/20 0.37
HDAC4 P56524 5/20 0.37
HDAC7 Q8WUI4 5/20 0.37
HDAC10 Q969S8 5/20 0.37
HDAC11 Q96DB2 5/20 0.37
HDAC8 Q9BY41 5/20 0.37
HDAC6 Q9UBN7 5/20 0.37
HDAC9 Q9UKV0 5/20 0.37
HDAC5 Q9UQL6 5/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36
CYP11B1 P15538 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27697969 0.83 NPC1 (0.49) NPC1RAB9ANOTUMPIK3CDCYP2A6
SCHEMBL9832665 0.83 ALDH1A1 (0.53) NPC1RAB9ANOTUMHDAC1HDAC2
SCHEMBL23923001 0.79 NOTUM (0.46) NPC1RAB9ANOTUMHDAC1HDAC2
SCHEMBL29379125 0.79 NOTUM (0.46) NPC1RAB9ANOTUMHDAC1HDAC2
SCHEMBL19834349 0.77 NOTUM (0.43) NPC1RAB9ANOTUMHDAC1HDAC2
SCHEMBL24784588 0.75 HDAC1 (0.55) NPC1RAB9ANOTUMCYP2A6HDAC1
SCHEMBL31590031 0.70 NOTUM (0.38) NOTUMKDM4EALDH1A1HPGDCASP3
SCHEMBL2438690 0.70 NPC1 (0.55) NPC1RAB9ANOTUMCYP2A6HDAC1
SCHEMBL4881364 0.70 ALOX15 (0.71) NPC1RAB9ANOTUMCYP2A6HDAC4
SCHEMBL19834409 0.70 NPC1 (0.49) NPC1RAB9ANOTUMPIK3CDCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10252997-B2 Monocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-04-09 US disclosed
US-20180079723-A1 MONOCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-03-22 US disclosed
EP-3279183-A1 MONOCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10252997-B2 Monocyclic compound FABP1, CPT1A, GOT2 NPC1 112/4885RAB9A 3714/4885NOTUM 284/4885
US-20180079723-A1 MONOCYCLIC COMPOUND FABP1, CPT1A, GOT2 NPC1 112/4885RAB9A 3714/4885NOTUM 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.